Perrigo Company plc Ordinary Shares (PRGO): Price and Financial Metrics

Perrigo Company plc Ordinary Shares (PRGO)

Today's Latest Price: $43.71 USD

0.94 (-2.11%)

Updated Jan 15 7:00pm

Add PRGO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

PRGO Stock Summary

  • With a one year PEG ratio of 1,297.86, PERRIGO Co plc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 96.94% of US stocks.
  • PERRIGO Co plc's stock had its IPO on December 17, 1991, making it an older stock than 82.18% of US equities in our set.
  • The volatility of PERRIGO Co plc's share price is greater than that of just 12.8% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PERRIGO Co plc are MTLS, QBAK, PEN, THR, and CUB.
  • Visit PRGO's SEC page to see the company's official filings. To visit the company's web site, go to

PRGO Stock Price Chart Interactive Chart >

Price chart for PRGO

PRGO Price/Volume Stats

Current price $43.71 52-week high $63.86
Prev. close $44.65 52-week low $40.01
Day low $43.50 Volume 2,426,200
Day high $45.20 Avg. volume 1,452,750
50-day MA $46.59 Dividend yield 2.06%
200-day MA $50.20 Market Cap 5.97B

Perrigo Company plc Ordinary Shares (PRGO) Company Bio

Perrigo Company develops, manufactures, and distributes generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The company was founded in 1887 and is based in Dublin, Ireland.

PRGO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$43.71$11 -75%

Below please find a table outlining a discounted cash flow forecast for PRGO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that PERRIGO Co plc ranked in the 21th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for PRGO, they are:

  • The company's balance sheet shows it gets 63% of its capital from equity, and 37% of its capital from debt. Its equity weight surpasses that of only 16.2% of free cash flow generating stocks in the Healthcare sector.
  • Its compound free cash flow growth rate, as measured over the past 5.53 years, is -0.11% -- higher than just 12.84% of stocks in our DCF forecasting set.
  • PERRIGO Co plc's weighted average cost of capital (WACC) is 10%; for context, that number is higher than 70.32% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of PERRIGO Co plc? See BSX, EHC, MTD, NUVA, and CNC.

PRGO Latest News Stream

Event/Time News Detail
Loading, please wait...

PRGO Latest Social Stream

Loading social stream, please wait...

View Full PRGO Social Stream

Latest PRGO News From Around the Web

Below are the latest news stories about PERRIGO Co plc that investors may wish to consider to help them evaluate PRGO as an investment opportunity.

RBC Capital Stick to Their Hold Rating for Perrigo Company plc By

RBC Capital Stick to Their Hold Rating for Perrigo Company plc | January 12, 2021

Perrigo And Michigan State University Announce Partnership To Advance Consumer Self-Care Innovation

DUBLIN and GRAND RAPIDS, Mich., Jan. 11, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, announced today a formal partnership with Michigan State University (MSU), connecting the university's clinical and research…

PR Newswire | January 11, 2021

Global Ibuprofen Market (2020 to 2024) - by Product, Dosage Form, Process & Region -

DUBLIN--(BUSINESS WIRE)--The "Global Ibuprofen Market (by Product, Dosage Form, Process & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to's offering. The global ibuprofen market is projected to reach US$7.54 billion in 2024, progressing at a CAGR of 2.47%, over the period 2020-2024. Companies Mentioned BASF SE IOL Chemicals & Pharmaceuticals Ltd. Perrigo Company PLC Shandong Xinhua Pharmaceutical Co., Ltd. S

Business Wire | January 11, 2021

Notable Insider Buys Of The Past Week: Howard Hughes, Party City, Perrigo And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. A beneficial owner began the new year with a …

Benzinga | January 9, 2021

Perrigo to Present Virtually at Upcoming Investor Conferences

DUBLIN, Dec. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that EVP and President of Consumer Self-Care Americas, Rich Sorota will present at the ICR Conference at 11:30 AM EST on Monday, January 11, 2021. Perrigo President & CEO Murray S. Kessler and…

PR Newswire | December 17, 2020

Read More 'PRGO' Stories Here

PRGO Price Returns

1-mo -5.16%
3-mo -3.83%
6-mo -22.68%
1-year -24.69%
3-year -50.16%
5-year -68.36%
YTD -2.26%
2020 -11.97%
2019 35.65%
2018 -55.08%
2017 5.58%
2016 -42.14%

PRGO Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full PRGO Dividend History

Continue Researching PRGO

Here are a few links from around the web to help you further your research on PERRIGO Co plc's stock as an investment opportunity:

PERRIGO Co plc (PRGO) Stock Price | Nasdaq
PERRIGO Co plc (PRGO) Stock Quote, History and News - Yahoo Finance
PERRIGO Co plc (PRGO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9864 seconds.